(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.
The three biggest winners today are Bebe stores, VerifyMe, and Beasley Broadcast Group.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Bebe stores (BEBE) | 3.61 | 14.6% | 2023-09-26 11:12:07 |
| 2 | VerifyMe (VRME) | 1.22 | 7.09% | 2023-09-26 12:52:08 |
| 3 | Beasley Broadcast Group (BBGI) | 0.93 | 6.44% | 2023-09-26 10:41:08 |
| 4 | Aemetis (AMTX) | 4.47 | 5.42% | 2023-09-26 03:10:06 |
| 5 | AngioDynamics (ANGO) | 7.37 | 4.99% | 2023-09-26 03:14:06 |
| 6 | Biolase (BIOL) | 1.70 | 4.94% | 2023-09-26 13:08:07 |
| 7 | Arcturus Therapeutics (ARCT) | 27.52 | 4.84% | 2023-09-26 12:16:02 |
| 8 | Beyond Meat (BYND) | 9.82 | 4.52% | 2023-09-26 12:16:16 |
| 9 | Liberty Media (LSXMB) | 23.80 | 4.43% | 2023-09-26 12:51:56 |
| 10 | Viking Therapeutics (VKTX) | 12.18 | 4.41% | 2023-09-26 12:18:12 |
The three biggest losers today are Bellicum Pharmaceuticals, Ebix, and AcelRx Pharmaceuticals.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Bellicum Pharmaceuticals (BLCM) | 0.32 | -29.97% | 2023-09-26 13:14:07 |
| 2 | Ebix (EBIX) | 10.65 | -10.43% | 2023-09-26 12:12:02 |
| 3 | AcelRx Pharmaceuticals (ACRX) | 0.60 | -10.39% | 2023-09-25 19:55:34 |
| 4 | Atara Biotherapeutics (ATRA) | 1.63 | -8.94% | 2023-09-26 07:17:06 |
| 5 | Ascent Solar Technologies (ASTI) | 6.23 | -7.7% | 2023-09-26 07:06:07 |
| 6 | Atossa Therapeutics (ATOS) | 0.77 | -7.1% | 2023-09-26 07:15:06 |
| 7 | SmileDirectClub (SDC) | 0.43 | -6.73% | 2023-09-26 12:17:38 |
| 8 | U.S. Gold Corp (USAU) | 3.05 | -6.15% | 2023-09-26 12:18:09 |
| 9 | Lumen Technologies (LUMN) | 1.31 | -6.12% | 2023-09-26 13:02:12 |
| 10 | Aurora Cannabis (ACB) | 0.70 | -5.75% | 2023-09-26 13:02:07 |
Winners today
1. Bebe stores (BEBE) – 14.6%
bebe stores, inc. does not have significant operations. Previously, it was engaged in the design, development, and production of women's apparel and accessories. The company marketed its products under the bebe and BEBE SPORT brand names through its retail stores; bebe.com, an online store; and 39 bebe outlet stores. It also offered its products through its 82 international licensee operated stores in 22 countries. bebe stores, inc. was founded in 1976 and is headquartered in Brisbane, California.
NASDAQ ended the session with Bebe stores rising 14.6% to $3.61 on Tuesday while NASDAQ slid 1.57% to $13,063.61.
Earnings Per Share
As for profitability, Bebe stores has a trailing twelve months EPS of $0.06.
PE Ratio
Bebe stores has a trailing twelve months price to earnings ratio of 60.17. Meaning, the purchaser of the share is investing $60.17 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -43.18%.
More news about Bebe stores.
2. VerifyMe (VRME) – 7.09%
VerifyMe, Inc., together with its subsidiary, PeriShip Global, LLC, operates as a technology solutions provider that specializes in products to connect brands with consumers and providing brands with end-to-end logistics management for their products. The company operates through two segments, VerifyMe Solutions and PeriShip Global Solutions. The VerifyMe Solutions segment offers technology solutions to connect brands with consumers allowing brand owners to gather business intelligence while engaging directly with their consumers. Its solutions provide brand protection and supply chain functions, such as counterfeit prevention, traceability, consumer engagement solutions, and authentication for labels, packaging, and products, as well as tamper-proof labels. The PeriShip Global Solutions segment offers predictive analytics for optimizing delivery of time and temperature sensitive perishable products. This segment's products include PeriTrack customer dashboard, an integrated web portal tool gives its customers an in-depth look at their shipping activities based on real-time data. It also provides call center, pre-transit, post-delivery, and weather/traffic services. The company has a strategic partnership with INX International Ink Company. The company was formerly known as LaserLock Technologies, Inc. and changed its name to VerifyMe, Inc. in July 2015. VerifyMe, Inc. was incorporated in 1999 and is headquartered in Lake Mary, Florida.
NASDAQ ended the session with VerifyMe rising 7.09% to $1.22 on Tuesday, after two successive sessions in a row of losses. NASDAQ slid 1.57% to $13,063.61, following the last session’s upward trend on what was an all-around down trend exchanging session today.
Earnings Per Share
As for profitability, VerifyMe has a trailing twelve months EPS of $-0.17.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -22.44%.
Volume
Today’s last reported volume for VerifyMe is 3840 which is 74.3% below its average volume of 14947.
Yearly Top and Bottom Value
VerifyMe’s stock is valued at $1.22 at 17:32 EST, way below its 52-week high of $2.27 and way higher than its 52-week low of $1.01.
Revenue Growth
Year-on-year quarterly revenue growth grew by 18.6%, now sitting on 25.91M for the twelve trailing months.
Moving Average
VerifyMe’s worth is above its 50-day moving average of $1.19 and way under its 200-day moving average of $1.48.
More news about VerifyMe.
3. Beasley Broadcast Group (BBGI) – 6.44%
Beasley Broadcast Group, Inc., a multi-platform media company, owns and operates radio stations in the United States. It also operates Houston Outlaws, an esports team that competes in the Overwatch League. The company was founded in 1961 and is headquartered in Naples, Florida.
NASDAQ ended the session with Beasley Broadcast Group rising 6.44% to $0.93 on Tuesday while NASDAQ slid 1.57% to $13,063.61.
Earnings Per Share
As for profitability, Beasley Broadcast Group has a trailing twelve months EPS of $-1.24.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -16.68%.
Moving Average
Beasley Broadcast Group’s worth is under its 50-day moving average of $0.99 and below its 200-day moving average of $1.00.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 400% and positive 102.3% for the next.
Yearly Top and Bottom Value
Beasley Broadcast Group’s stock is valued at $0.93 at 17:32 EST, way below its 52-week high of $1.39 and way above its 52-week low of $0.74.
More news about Beasley Broadcast Group.
4. Aemetis (AMTX) – 5.42%
Aemetis, Inc. operates as a renewable natural gas and renewable fuels company in North America and India. It operates through three segments: California Ethanol, Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the acquisition, development, and commercialization of negative carbon intensity products and technologies that replace traditional petroleum-based products. It sells biodiesel primarily to government oil marketing companies, transport companies, resellers, distributors, and private refiners through its own sales force and independent sales agents, as well as to brokers who resell the product to end-users. The company also produces and sells ethanol; and wet distillers grains, distillers corn oil, and condensed distillers solubles to dairies and feedlots as animal feed. In addition, it produces dairy biogas; produces and sells high-grade alcohol and various feed products, as well as hand sanitizers; and researches and develops conversion technologies using waste feedstocks to produce biofuels and biochemicals. The company was formerly known as AE Biofuels, Inc. and changed its name to Aemetis, Inc. in November 2011. Aemetis, Inc. was founded in 2005 and is headquartered in Cupertino, California.
NASDAQ ended the session with Aemetis rising 5.42% to $4.47 on Tuesday, following the last session’s upward trend. NASDAQ fell 1.57% to $13,063.61, following the last session’s upward trend on what was an all-around down trend exchanging session today.
Earnings Per Share
As for profitability, Aemetis has a trailing twelve months EPS of $-3.54.
Revenue Growth
Year-on-year quarterly revenue growth declined by 31.5%, now sitting on 185.83M for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Aemetis’s EBITDA is 2.37.
Yearly Top and Bottom Value
Aemetis’s stock is valued at $4.47 at 17:32 EST, way below its 52-week high of $8.99 and way higher than its 52-week low of $1.16.
Volume
Today’s last reported volume for Aemetis is 867605 which is 43.75% above its average volume of 603542.
More news about Aemetis.
5. AngioDynamics (ANGO) – 4.99%
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
NASDAQ ended the session with AngioDynamics jumping 4.99% to $7.37 on Tuesday while NASDAQ dropped 1.57% to $13,063.61.
Earnings Per Share
As for profitability, AngioDynamics has a trailing twelve months EPS of $-1.31.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -13.06%.
More news about AngioDynamics.
6. Biolase (BIOL) – 4.94%
BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, pain therapy, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces, and teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.
NASDAQ ended the session with Biolase jumping 4.94% to $1.70 on Tuesday, following the last session’s upward trend. NASDAQ fell 1.57% to $13,063.61, following the last session’s upward trend on what was an all-around negative trend trading session today.
Earnings Per Share
As for profitability, Biolase has a trailing twelve months EPS of $-222.04.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -200.06%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Biolase’s EBITDA is 0.23.
Moving Average
Biolase’s worth is way below its 50-day moving average of $4.96 and way below its 200-day moving average of $27.48.
More news about Biolase.
7. Arcturus Therapeutics (ARCT) – 4.84%
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.
NASDAQ ended the session with Arcturus Therapeutics rising 4.84% to $27.52 on Tuesday while NASDAQ fell 1.57% to $13,063.61.
Earnings Per Share
As for profitability, Arcturus Therapeutics has a trailing twelve months EPS of $3.07.
PE Ratio
Arcturus Therapeutics has a trailing twelve months price to earnings ratio of 8.96. Meaning, the purchaser of the share is investing $8.96 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 35.22%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Arcturus Therapeutics’s EBITDA is 2.07.
Moving Average
Arcturus Therapeutics’s worth is under its 50-day moving average of $30.53 and way above its 200-day moving average of $23.51.
More news about Arcturus Therapeutics.
8. Beyond Meat (BYND) – 4.52%
Beyond Meat, Inc. develops, manufactures, markets, and sells plant-based meat products in the United States and internationally. The company sells a range of plant-based meat products across the platforms of beef, pork, and poultry. It sells its products through grocery, mass merchandiser, club, convenience, and natural retailer channels, as well as various food-away-from-home channels, including restaurants, foodservice outlets, and schools. The company was formerly known as Savage River, Inc. and changed its name to Beyond Meat, Inc. in September 2018. Beyond Meat, Inc. was founded in 2009 and is headquartered in El Segundo, California.
NASDAQ ended the session with Beyond Meat rising 4.52% to $9.82 on Tuesday, after three sequential sessions in a row of losses. NASDAQ fell 1.57% to $13,063.61, following the last session’s upward trend on what was an all-around negative trend exchanging session today.
Earnings Per Share
As for profitability, Beyond Meat has a trailing twelve months EPS of $-4.1.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Beyond Meat’s stock is considered to be overbought (>=80).
Moving Average
Beyond Meat’s worth is way below its 50-day moving average of $14.09 and way below its 200-day moving average of $14.40.
Volatility
Beyond Meat’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.33%, a negative 1.02%, and a positive 3.00%.
Beyond Meat’s highest amplitude of average volatility was 2.40% (last week), 2.33% (last month), and 3.00% (last quarter).
Sales Growth
Beyond Meat’s sales growth is 7.4% for the ongoing quarter and 4.6% for the next.
More news about Beyond Meat.
9. Liberty Media (LSXMB) – 4.43%
The Liberty SiriusXM Group, through its subsidiaries, engages in the entertainment business in the United States and Canada. It features music, sports, entertainment, comedy, talk, news, traffic, weather channels, podcast, and infotainment services through proprietary satellite radio systems, as well as streamed through applications for mobile and home devices, and other consumer electronic equipment. It also offers connected vehicle services; a suite of data services that include graphical weather, fuel prices, sports schedules and scores, and movie listings; and traffic information services, which provide information as to road closings, traffic flow and incident data to consumers with compatible in-vehicle navigation systems, and real-time weather services in vehicles, boats, and planes. In addition, the company operates a music, comedy, and podcast streaming platform. Further, it offers ad-supported radio services; Pandora Plus, a radio subscription service; and Pandora Premium, an on-demand subscription service. Additionally, the company distributes satellite radios through automakers and retailers, as well as through its website. As of December 31, 2021, it served approximately 34.0 million subscribers through Sirius XM and approximately 6.4 million subscribers through Pandora. The Liberty SiriusXM Group is based in Englewood, Colorado. The Liberty SiriusXM Group operates as a subsidiary of Liberty Media Corporation.
NASDAQ ended the session with Liberty Media rising 4.43% to $23.80 on Tuesday while NASDAQ fell 1.57% to $13,063.61.
: liberty media proposes combining sirius XM and liberty sirius XM tracking stock to form new sirius XMShares of Liberty Media Corp.’s Liberty Sirius XM tracking stock shot up 11.6% in premarket trading, while Sirius XM Holdings Inc.’s stock slid 4.5% toward a three-month low, after Liberty Media said it proposed that the two stocks combine to form a new public company named New SiriusXM.
Earnings Per Share
As for profitability, Liberty Media has a trailing twelve months EPS of $2.6.
PE Ratio
Liberty Media has a trailing twelve months price to earnings ratio of 9.15. Meaning, the purchaser of the share is investing $9.15 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.27%.
Volatility
Liberty Media’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.22%, a negative 1.66%, and a positive 4.24%.
Liberty Media’s highest amplitude of average volatility was 0.22% (last week), 2.39% (last month), and 4.24% (last quarter).
Earnings Before Interest, Taxes, Depreciation, and Amortization
Liberty Media’s EBITDA is 1.63.
Yearly Top and Bottom Value
Liberty Media’s stock is valued at $23.80 at 17:32 EST, way under its 52-week high of $47.43 and above its 52-week low of $22.19.
More news about Liberty Media.
10. Viking Therapeutics (VKTX) – 4.41%
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
NASDAQ ended the session with Viking Therapeutics jumping 4.41% to $12.18 on Tuesday, after five successive sessions in a row of losses. NASDAQ slid 1.57% to $13,063.61, following the last session’s upward trend on what was an all-around negative trend trading session today.
Earnings Per Share
As for profitability, Viking Therapeutics has a trailing twelve months EPS of $-0.9.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -26.88%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Viking Therapeutics’s stock is considered to be overbought (>=80).
More news about Viking Therapeutics.
Losers Today
1. Bellicum Pharmaceuticals (BLCM) – -29.97%
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.
NASDAQ ended the session with Bellicum Pharmaceuticals dropping 29.97% to $0.32 on Tuesday, following the last session’s downward trend. NASDAQ slid 1.57% to $13,063.61, following the last session’s upward trend on what was an all-around bearish trend exchanging session today.
Earnings Per Share
As for profitability, Bellicum Pharmaceuticals has a trailing twelve months EPS of $-0.89.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -154.47%.
More news about Bellicum Pharmaceuticals.
2. Ebix (EBIX) – -10.43%
Ebix, Inc., together with its subsidiaries, provides on-demand infrastructure software exchanges and e-commerce services to the insurance, financial, travel, cash remittance, and healthcare industries in the United States and internationally. The company develops and deploys insurance and reinsurance exchanges on an on-demand basis using software-as-a-service (SaaS) enterprise solutions in the areas of customer relationship management, front-end and back-end systems, and outsourced administrative and risk compliance solutions. Its EbixCash exchange related products and services include gift cards; travel exchanges services; money transfer services; foreign exchange and outward remittance services; consumer payment services; and on-demand technology to various providers in the areas of lending, wealth and asset management, and travel. The company's insurance exchanges related products and services include SaaS platform and related services; licensing of software; and professional services comprising setup, customization, training, or consulting. Its risk compliance services cover certificates of insurance creation and tracking; consulting services, such as project management, integration, development, and testing; and business process outsourcing services, including domain intensive project management, system consulting services, and claims adjudication/settlement services. The company was formerly known as Delphi Systems, Inc. and changed its name to Ebix, Inc. in December 2003. Ebix, Inc. was founded in 1976 and is headquartered in Johns Creek, Georgia.
NASDAQ ended the session with Ebix sliding 10.43% to $10.65 on Tuesday while NASDAQ slid 1.57% to $13,063.61.
Earnings Per Share
As for profitability, Ebix has a trailing twelve months EPS of $1.09.
PE Ratio
Ebix has a trailing twelve months price to earnings ratio of 9.77. Meaning, the purchaser of the share is investing $9.77 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.64%.
Volatility
Ebix’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.06%, a negative 1.49%, and a positive 5.13%.
Ebix’s highest amplitude of average volatility was 0.75% (last week), 3.03% (last month), and 5.13% (last quarter).
Earnings Before Interest, Taxes, Depreciation, and Amortization
Ebix’s EBITDA is 1.05.
More news about Ebix.
3. AcelRx Pharmaceuticals (ACRX) – -10.39%
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.
NASDAQ ended the session with AcelRx Pharmaceuticals dropping 10.39% to $0.60 on Tuesday while NASDAQ slid 1.57% to $13,063.61.
Earnings Per Share
As for profitability, AcelRx Pharmaceuticals has a trailing twelve months EPS of $-3.06.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -68.59%.
Moving Average
AcelRx Pharmaceuticals’s worth is way under its 50-day moving average of $0.95 and way under its 200-day moving average of $1.24.
More news about AcelRx Pharmaceuticals.
4. Atara Biotherapeutics (ATRA) – -8.94%
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
NASDAQ ended the session with Atara Biotherapeutics sliding 8.94% to $1.63 on Tuesday, following the last session’s downward trend. NASDAQ fell 1.57% to $13,063.61, following the last session’s upward trend on what was an all-around negative trend exchanging session today.
Earnings Per Share
As for profitability, Atara Biotherapeutics has a trailing twelve months EPS of $-2.97.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -229.9%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 98.1%, now sitting on 6.86M for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Atara Biotherapeutics’s EBITDA is 11.05.
Yearly Top and Bottom Value
Atara Biotherapeutics’s stock is valued at $1.63 at 17:32 EST, way under its 52-week high of $5.64 and way above its 52-week low of $1.25.
More news about Atara Biotherapeutics.
5. Ascent Solar Technologies (ASTI) – -7.7%
Ascent Solar Technologies, Inc. designs, manufactures, and sells copper-indium-gallium-diselenide photovoltaic products for aerospace, defense, emergency management, and consumer/OEM applications. It offers outdoor solar chargers. The company markets and sells its products through OEMs, system integrators, distributors, retailers, and e-commerce companies. Ascent Solar Technologies, Inc. was incorporated in 2005 and is based in Thornton, Colorado.
NASDAQ ended the session with Ascent Solar Technologies sliding 7.7% to $6.23 on Tuesday while NASDAQ dropped 1.57% to $13,063.61.
Earnings Per Share
As for profitability, Ascent Solar Technologies has a trailing twelve months EPS of $-119.38.
Revenue Growth
Year-on-year quarterly revenue growth declined by 84.1%, now sitting on 244.53k for the twelve trailing months.
Yearly Top and Bottom Value
Ascent Solar Technologies’s stock is valued at $6.23 at 17:32 EST, way below its 52-week high of $1,494.00 and above its 52-week low of $6.10.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Ascent Solar Technologies’s EBITDA is 51.09.
Moving Average
Ascent Solar Technologies’s worth is way below its 50-day moving average of $12.52 and way under its 200-day moving average of $108.90.
More news about Ascent Solar Technologies.
6. Atossa Therapeutics (ATOS) – -7.1%
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
NASDAQ ended the session with Atossa Therapeutics dropping 7.1% to $0.77 on Tuesday while NASDAQ dropped 1.57% to $13,063.61.
Earnings Per Share
As for profitability, Atossa Therapeutics has a trailing twelve months EPS of $-0.26.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -26.89%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is a negative 16.7% and a negative 16.7%, respectively.
Moving Average
Atossa Therapeutics’s worth is way below its 50-day moving average of $0.93 and under its 200-day moving average of $0.82.
Volume
Today’s last reported volume for Atossa Therapeutics is 393564 which is 52.16% below its average volume of 822774.
Yearly Top and Bottom Value
Atossa Therapeutics’s stock is valued at $0.77 at 17:32 EST, way below its 52-week high of $1.39 and way higher than its 52-week low of $0.50.
More news about Atossa Therapeutics.
7. SmileDirectClub (SDC) – -6.73%
SmileDirectClub, Inc., an oral care company, offers clear aligner therapy treatment. The company manages the end-to-end process, which include marketing, aligner manufacturing, fulfillment, treatment by a customer's dentist or orthodontist, and facilitating remote clinical monitoring through a network of orthodontists and general dentists through its proprietary teledentistry platform, SmileCheck in the United States, Puerto Rico, Canada, Australia, the United Kingdom, New Zealand, Ireland, Hong Kong, Germany, Singapore, France, Spain, and Austria. It also offers aligners, impression and whitening kits, whitening gels, and retainers; and toothbrushes, toothpastes, water flossers, SmileSpa, and various ancillary oral care products. The company was founded in 2014 and is headquartered in Nashville, Tennessee.
NASDAQ ended the session with SmileDirectClub sliding 6.73% to $0.43 on Tuesday while NASDAQ slid 1.57% to $13,063.61.
Earnings Per Share
As for profitability, SmileDirectClub has a trailing twelve months EPS of $-2.628.
Earnings Before Interest, Taxes, Depreciation, and Amortization
SmileDirectClub’s EBITDA is 2.19.
Volume
Today’s last reported volume for SmileDirectClub is 501990 which is 76.88% below its average volume of 2172110.
More news about SmileDirectClub.
8. U.S. Gold Corp (USAU) – -6.15%
U.S. Gold Corp. engages in the exploration and development of gold and precious metals in the United States. It also explores for copper and silver deposits. The company holds 100% interests in the CK Gold project, which consists of various mining leases and other mineral rights covering approximately 1,120 acres in Laramie County, Wyoming; the Keystone project that consists of 601 unpatented lode mining claims covering approximately 20 square miles in Eureka County, Nevada; and the Challis Gold project, which consists of 77 unpatented lode mining claims covering approximately 1,710 acres in Lemhi County, Idaho. It also has earn-in agreement to acquire a 50% ownership interest in the Maggie Creek project located in Eureka County, Nevada. The company was formerly known as Dataram Corporation and changed its name to U.S. Gold Corp. in June 2017. U.S. Gold Corp. is based in Elko, Nevada.
NASDAQ ended the session with U.S. Gold Corp dropping 6.15% to $3.05 on Tuesday, after five sequential sessions in a row of losses. NASDAQ fell 1.57% to $13,063.61, following the last session’s upward trend on what was an all-around down trend trading session today.
Earnings Per Share
As for profitability, U.S. Gold Corp has a trailing twelve months EPS of $-0.92.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -36.19%.
More news about U.S. Gold Corp.
9. Lumen Technologies (LUMN) – -6.12%
Lumen Technologies, Inc., a facilities-based technology and communications company, provides various integrated products and services under the Lumen, Quantum Fiber, and CenturyLink brands to business and residential customers in the United States and internationally. The company operates in two segments, Business and Mass Markets. It offers compute and application services, such as edge cloud services, IT solutions, unified communication and collaboration solutions, colocation and data center services, content delivery services, and managed security services; and IP and data services, including VPN data network, Ethernet, internet protocol (IP), and voice over internet protocol. The company also provides fiber infrastructure services comprising high bandwidth optical wavelength networks; and unlit optical fiber and related professional services. In addition, it offers voice and other services, including private line services, a direct circuit or channel specifically dedicated for connecting two or more organizational sites; a portfolio of traditional time division multiplexing voice services; and synchronous optical network-based ethernet, legacy data hosting services, and conferencing services. The company was formerly known as CenturyLink, Inc. and changed its name to Lumen Technologies, Inc. in September 2020. The company was incorporated in 1968 and is headquartered in Monroe, Louisiana.
NYSE ended the session with Lumen Technologies dropping 6.12% to $1.31 on Tuesday, after five sequential sessions in a row of losses. NYSE fell 1.36% to $15,381.58, following the last session’s upward trend on what was an all-around bearish trend trading session today.
Earnings Per Share
As for profitability, Lumen Technologies has a trailing twelve months EPS of $-10.63.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Lumen Technologies’s stock is considered to be overbought (>=80).
Volume
Today’s last reported volume for Lumen Technologies is 8193780 which is 56.91% below its average volume of 19017400.
Volatility
Lumen Technologies’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.92%, a negative 0.25%, and a positive 4.10%.
Lumen Technologies’s highest amplitude of average volatility was 3.92% (last week), 3.26% (last month), and 4.10% (last quarter).
More news about Lumen Technologies.
10. Aurora Cannabis (ACB) – -5.75%
Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Leduc, Canada.
NYSE ended the session with Aurora Cannabis dropping 5.75% to $0.70 on Tuesday while NYSE slid 1.36% to $15,381.58.
Earnings Per Share
As for profitability, Aurora Cannabis has a trailing twelve months EPS of $-5.81.
Volatility
Aurora Cannabis’s last week, last month’s, and last quarter’s current intraday variation average was a negative 4.79%, a positive 3.80%, and a positive 4.88%.
Aurora Cannabis’s highest amplitude of average volatility was 5.98% (last week), 10.00% (last month), and 4.88% (last quarter).
More news about Aurora Cannabis.
Stay up to date with our winners and losers daily report
